Date Published 
September 2014

Page Count
 141

Additional Info 
Single-site, country, and global licenses are multi-user, searchable, and cut-and-paste ready PDFs delivered by e-mail.

 

For Global Licenses, Multi-Reports Orders, Discounts or Order Questions.  

Contact:
Dan Miller
Marketing Associate
781-972-5492 

 


IPR Bundle Button

 

Companies that Purchased this Report

AbbVie Inc
Agenus Inc
Anticancer Fund
Bayer Healthcare Pharmaceuticals
Charles River Labs
Compugen Ltd
ImmuneXcite
Jackson Lab
Janssen R&D LLC
Johnson & Johnson
Medytox
Merck & Co.
Northwest Biotherapeutics Inc
Pfizer Canada Inc
Polynoma LLC
Shionogi & Co. Ltd
STEMCELL Technologies Inc
Targovax AS
Takeda Pharmaceutical Co. Ltd
VBI Vaccines Inc
Verastem Inc
Victoria University of Wellington



Cancer Immunotherapy: immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapies - Overview

 

Cancer-Immunotherapy 

This report focuses on the rising potential for the newest and most promising of cancer treatments: cancer immunotherapy. Cancer immunotherapy was once just a dream in the minds of physicians, clinicians and patients, but only recently (2010s era) has it actually been within reasonable reach. Cancer Immunotherapy: immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapies covers three principle therapies that have been in the works for cancer patients.

One principle therapy that has been on the rise is checkpoint inhibitors. Checkpoint inhibitors are a class of monoclonal antibodies that inhibit pathways responsible for blocking the response of T-cells to antigens. Not only have results from clinical trials of these therapeutics been promising, but treatments have already been approved both in the U.S. and Europe for metastatic melanoma. There are several agents and targets covered in this section, including the September 5, 2014 approval of Merck's PD-1 inhibitor: pembrolizumab (Keytruda), as well as the future outlook of potential combination checkpoint inhibitor therapies.   

Another principle therapy under investigation are anticancer vaccines. This is another major strategy surfacing in cancer therapeutics and, unlike traditional vaccines which are given to prevent illness (i.e. smallpox, measles, and pertussis), these vaccines are given to patients who already have cancer and are designed to elicit an antitumor response to even the most aggressive of cancers. Though this is a theoretically good approach to combat cancer, there have been an unfortunate number of clinical failures and the industry has gained only one U.S. approved anticancer vaccine. Combination therapies are also a possible route these vaccines will take in the future. 

Finally, the last therapy addressed in this report is adoptive cellular immunotherapy. Adoptive cellular immunotherapy is when syngeneic activated T-cells are infused in patients to attack their cancers. There are a few types of cellular immunotherapies including: tumor infiltrating lymphocyte (TIL) therapy, genetically engineered T cells bearing chimeric antigen receptors (CARs), and recombinant TCR technology. Improving these therapies is the goal over the next few years and researchers have been working heavily to commercialize these products and technologies.

The report is further coupled with an in-depth introduction and history as well as with data for market outlook. Also featured in this report are exclusive interviews with three high-end professors, researchers and CEOs:
• Adil Daud, MD, Clinical Professor, Department of Medicine (Hematology/Oncology), University of California at San Francisco (UCSF); Director, Melanoma Clinical Research, UCSF Helen Diller Family Comprehensive Cancer Center.
• Matthew Lehman, Chief Executive Officer, Prima BioMed (a therapeutic cancer vaccine company with headquarters in Sydney, Australia).
• Marcela Maus, MD, PhD, the Director of Translational Medicine and Early Clinical Development, Translational Research Program, Abramson Cancer Center, University of Pennsylvania in Philadelphia.

Furthermore, Insight Pharma Reports also conducted and analyzed survey data representing a population sample from the R&D industry. This survey depicts market outlook, and portrays industry opinions and perspectives.